Choroid plexus (CP) forms an anatomically functional barrier between the blood and cerebrospinal fluid (CSF) that dictates the cellular and humoral composition of the CSF. The immunological response of CP to inflammatory stimuli, such as cancer, remains unclear. Here, we find that CP immune composition is sensitive to the systemic and intracerebral milieu, and that IFN-γ affects CP cellularity, viral load, and the humoral profile in the steady state as well as in the presence of metastatic cancer. We show that the circulation-derived leptomeningeal monocye-macrophages entering the CP through CP promote the growth of leptomeningeal metastasis (LM) by perturbing the environment with factors of pro- and anti-inflammatory cytokines. Functional manipulation of Type II interferon pathway mediately within inflamed leptomeninges revealed that IFN-γ can serve as a dominant signal, further recruiting peripheral myeloid cells and activating their protective anti-tumor response. This preclinical strategy was sufficient to control the growth of syngeneic LM cancer cells and delay the onset of lethal LM.

LMD-17. NEOPLASTIC MENINGITIS IN LUNG CANCER: RETROSPECTIVE REVIEW OF CLINICAL FEATURES, DIAGNOSIS AND OUTCOME IN ADULT PATIENTS.

Florence Yorio1, Juan Bautista Blaquier1,2, Bernadette Calabrese1, Sebastián Ceratto1, Blanca Diez1, Alejandro Mugger1,3, Fleni, Buenos Aires, Argentina, 3CEMIC, Buenos Aires, Argentina

BACKGROUND: Neoplastic Meningitis (NM) is a lethal complication of cancer. Its incidence is rising and in 10% of the cases NM is the first manifestation of the disease. Diagnosis relies on a clinico-pathological correlation, CSF analysis, and finding of malignant cells in cerebrospinal fluid (CSF). Diagnosis is often challenging due to the low sensitivity of the different diagnostic modalities. The aim of this study is to identify the clinical features, diagnosis, treatment and outcome of lung cancer patients with NM.

METHODS: Clinical records from patients with diagnosis of lung cancer and NM between 2011–2021 were retrospectively reviewed at a tertiary neurological center in Buenos Aires, Argentina. RESULTS: Twenty-seven patients were included. Median age was 68 years (IQR 56–84), 17 (63%) were female. Twenty-four patients had non-small cell lung cancer (91% adenocarcinoma), had neuroendocrine lung cancer and one small cell lung cancer. In 19 (70%), meningeal involvement was a result of progressive disease from previously diagnosed cancer. In 12 (44%) patients meningeal disease developed posterior to parenchymal brain metastases surgical approach, 5 (41%) with posterior fossa craniotomy. Headache was the most frequent symptom (53%), CSF analysis was abnormal in 13 (48%) patients, with positive cytology in 10 (37%). Meningeal enhancement was detected with magnetic resonance imaging of brain or spine in 24 (89%) patients. Twenty-one (77%) patients received oncological treatment, 14 (51%) with chemotherapy (8 systemic, 3 intrathecal and 3 intrathecal plus systemic). Thirty (48%) patients underwent treatment with either immunotherapy or targeted therapy. Patients underwent whole brain radiotherapy. Median overall survival was 7 months (CI 95%: 3.5–10.4). CONCLUSION: Headache was the most frequent symptom. Ninety-two percent of patients had meningeal pathological enhancement in high-quality MRI with gadolinium contrast of brain and spine. Despite median survival was poor, small subsets of these patients (22%) survived more than 2 years.

LMD-18. DETECTION AND SERIAL MONITORING OF CSF ctDNA IN BREAST CANCER LEPTOMENINGEAL DISEASE (BCLM)

American Fitzpatrick1, Marjan Iravani1, Alicio Okines1, Adam Mills1, Mark Harries1, Andrew Tutt2, Clare Isaacks2, 1Institute of Cancer Research, London, UK, 2Royal Marsden Hospital, London, UK, 3Guys Cancer Centre, London, UK

BACKGROUND: CSF cytology is the gold standard diagnostic test for BCLM, but is hampered by a low sensitivity, often necessitating repeated lumbar puncture to confirm or refute the diagnosis. Furthermore, during the treatment of BCLM, there is no robust quantitative response tool to guide treatment decisions. Material and METHODS: cfDNA was obtained from CSF and plasma in patients with breast cancer undergoing investigation for BCLM (n = 28) and during subsequent intrathecal treatment (n = 13). Using a low pass whole genome sequencing (dpWGS) and estimation of the cfDNA fraction was performed. Results were validated by mutation-specific digital droplet PCR (ddPCR). RESULTS: 22/28 cases had confirmed BCLM by positive MRI and/or CSF cytology. The remaining 6/28 had suspected but non-confirmed BCLM, and at median 20 months follow up, these patients were BCLM-free. CSF cfDNA fraction was significantly elevated (median 57.5 IQR 38.3–149.9%) in confirmed BCLM compared to 6 non-confirmed BCLM (median 5.0, IQR 0.0 – 6.7%) (p = 0.001). cfDNA fraction was detected in BCLM confirmed cases regardless of negative cytology or MRI. Plasma cfDNA fraction was only detected in extra-cranial disease progression, cfDNA fraction was concordant with mutant allele fraction measured by ddPCR (n = 118 samples). Serial CSF cfDNA fraction during intrathecal treatment showed dynamic changes, while CSF cytology and MRI were often unchanged or equivocal. Early reduction in CSF cfDNA fraction was associated with longer responses to intrathecal therapy. Further, rising cfDNA fraction during intrathecal chemotherapy could be detected up to 6 weeks before relapse in neurological symptoms, cytology or MRI. CONCLUSION: Measuring CSF cfDNA fraction during intrathecal chemotherapy could lead to timely and accurate diagnosis. During intrathecal chemotherapy, CSF cfDNA also provides a quantitative response biomarker to help guide clinical management in this difficult treatment scenario.

LMD-19. ANATOMIC AND SURGICAL FACTORS PREDICT DEVELOPMENT OF LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC MELANOMA

Steven Lowe1, Christopher P. Wang2, Amanda Briscoe3, Kamran Ahmed1, Michael A. Vogelbaum4, James K. C. Liu5; 1‘H Lee Moffitt Cancer Center, Tampa, FL, USA, 2University of South Florida College of Medicine, Tampa, FL, USA

BACKGROUND: Leptomeningeal disease (LMD) is a devastating complication of systemic malignancy, portending a poor prognosis with an estimated median survival of 4–6 weeks if left untreated. Several reports have suggested surgical resection, particularly of dural and periventricular lesions, as an additional causative factor. Herein, we explore if surgical and anatomical factors are correlated with development of LMD in patients with melanoma brain metastases.

METHODS: Patients treated at our institution between 1999–2019 for primary melanoma with brain metastases were matched 1:1 based on age, CD91/10 coding, 1,079 patients with melanoma brain metastases and appropriate imaging were identified, and 834 patients with a minimum of 3 months’ follow-up were included. Patients were dichotomized by development of LMD or lack thereof. General demographic information, surgical and anatomical data, and ventricular access during surgery were investigated as possible correlative factors for the development of LMD. RESULTS: On univariate analysis, female gender (p = 0.033), presence of dural metastases (p = 0.018), presence of periventricular lesions (p < 0.001), presence of intraventricular lesions (p < 0.001), and ventricular access during surgery (p < 0.001) were significantly associated with LMD. Patients undergoing surgery, or those undergoing surgery without ventricular access, were not at higher risk of LMD. Administration of immunotherapy, either as first-line or salvage therapy, did not impact rates of LMD. On multivariate analysis, female gender (p = 0.033), presence of periventricular lesions (p < 0.001), presence of intraventricular lesions (p < 0.002), and presence of dural metastases (p = 0.032) were significantly associated with development of LMD. In patients who had surgery, iatrogenic ventricular access (p < 0.001) was significantly correlated with LMD. CONCLUSIONS: In a retrospective cohort of patients with melanoma metastatic to the brain, those patients with pre-existing lesions in contact with the CSF space are more likely to develop LMD than those who do not. In addition, iatrogenic access to the CSF space during surgery is highly correlated with LMD development.

LMD-20. IMMUNE SUPPRESSIVE MACROPHAGES AND SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) EXPRESSION ARE COMMON IN MELANOMA LEPTOMENINGEAL DISEASE

Hindia Najm1, Anatiana Marisetty2, Craig Horbinski3, Jared Burks4, Amy B Heimberger3, 1Northwestern University School of Medicine, Chicago, IL, USA, 2Baylor College of Medicine, Houston, TX, USA, 3The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Leptomeningeal disease (LMD) in melanoma patients is associated with significant neuroimmunopathological and has a dismal outcome with a median survival of 1.8 months. Despite the therapeutic benefit of targeted therapies and immunotherapies for most stages of Stage IV melanoma, patients with LMD do not typically benefit. A deeper understanding of the tumor microenvironment (TME) of LMD may provide more appropriate therapeutic selection. A retrospective analysis of subjects who underwent surgical resection with LMD (n = 8) were profiled with seven color multiplex to evaluate the expression of the global immune suppressive hub - the signal transducer and activator of transcription 3 (STAT3) and for the presence of CD3 T cells, CD68+ monocytes, CD163 immune suppressive macrophages, CD11c+ antigen presenting cells (APCs) in association with the melanoma tumor marker S100B and DAPI for cellular nuclear identification. High-resolution cellular imaging and quantification was conducted using the Akoya Vectra Polar, CD163+ macrophage is the most frequent immune cell population in the LMD TME. Occasional CD3+ T cells and CD11c+ APC are also identified, although the latter has concurrent expression of CD163. STAT3 nuclear localization is heterogeneously expressed in the cell population in the LMD TME. In patients with melanoma with brain metastasis were compiled into a database based on August 2021.
of LMD is largely devoid of CD3+ T cells, but is enriched for immune suppression and innate immunity.

LMD-21. HEADACHE IMPROVEMENT PREDICTS SURVIVAL AFTER CSF DIVERSION IN LEPTOMENINGEAL DISEASE

Adam Robin1, Sameeh Haider1, Natalie Dusteiano2, Anne Reiner3, Viviane Talbar2, Jacob Pawloski2, 1Henry Ford Health System, Detroit, MI, USA, 2Memorial Sloan Kettering Cancer Center, New York, NY, USA, 3Henry Ford Health Center, Detroit, MI, USA

BACKGROUND: Leptomeningeal carcinomatosis (LMD) is a seeding of the leptomeninges by malignant cells. Clinical, treatment and patient-related factors have been described in patients with LMD. Current data are limited by small sample size, particularly in patients undergoing ventriculo-peritoneal shunting (VPS) as part of the treatment regimen. OBJECTIVE: This study presents the largest cohort of LMD patients in the literature undergoing cerebrospinal fluid (CSF) diversion and seeks to identify prognostic factors related to survival. METHODS: A retrospective review of patients diagnosed with LMD between 2010 and 2016 at a quaternary referral center was performed. Cox proportional hazards modeling was utilized to identify variables associated with improved overall survival from LMD diagnosis. Overall survival was depicted using Kaplan-Meier methodology. Competing risk methodology was used to identify variables associated with VPS, considering death as a competing event. RESULTS: On the 314 patients identified, 112 underwent VPS placement. The median overall survival from LMD diagnosis was 3.9 months (95% CI: 3.2–4.4). The presence of headaches, increased opening pressure, and gait difficulty increased the likelihood of VPS placement (p<0.005). VPS older than year 2015 and Karnofsky Performance Status (KPS), higher opening pressure and CSF nucleated cell count (NCC) increased the risk of death (all p<0.05). Patients reporting headache improvement after VPS had better survival (p=0.05). CONCLUSIONS: Headache, increased opening pressure and gait instability were associated with higher rate of VPS placement and may portend more aggressive disease. Headache improvement following VPS is a favorable prognostic sign, suggesting survival advantage for patients with hydrocephalus undergoing VPS. Age, KPS, VPS, opening pressure, CSF NCC, concomitant vaginal metastases and histology-specific molecular profile impact survival.

LMD-22. CLINICOPATHOLOGICAL SPECTRUM OF LEPTOMENINGEAL METASTASES: A 3 YEAR RETROSPECTIVE STUDY

Saloni Pahuja, Anila Sharma, Meenakshi Kamboj, Anurag Mehta; RGIRC, Delhi, India

OBJECTIVE: Cytological examination of cerebrospinal fluid is a widely used cost effective, simple procedure and a reliable routine diagnostic test. CSF cytology helps in detection of inflammatory diseases of the CNS, diagnosis of subarachnoid haemorrhage and the identification of malignant cells in metastatic or rarely primary CNS malignancies. Leptomeningeal metastases (LM) is estimated to occur in 5% of all patients with cancer. It has a higher propensity to occur in solid tumours compared to haematolymphoid malignancies. In view of poor prognosis, early diagnosis may aid in appropriate tumour staging and aggressive therapeutic intervention. METHODS: All the samples of CSF received in the Department of Laboratory Medicine, University of Toronto, Toronto, ON, Canada, 2Department of Medicine, Sunnybrook Hospital, University of Toronto, Toronto, ON, Canada, 3Department of Family Medicine, University of Toronto, Women's College Hospital, Toronto, ON, Canada, 4Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada, 5Division of Neuropathology, University of Toronto, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada

BACKGROUND: Targeted therapies have been hypothesized to prolong survival in patients with metastatic brain disease (IMD) but, paradoxically, to increase IMD incidence by improving systemic disease control and prolonging survival from the primary tumor. The real-world benefits of targeted therapy in management of patients with IMD are unclear, as clinical trials have excluded patients with IMD and lacked endpoints reporting intracranial outcomes. METHODS: This retrospective cohort study included all patients in Ontario, Canada, diagnosed with IMD from 2003 to 2018 with primary diagnoses of breast cancer, lung or colorectal cancer, or metastatic control patients matched by primary disease without IMD. Kaplan-Meier and multivariable Cox regression analyses were performed to compare overall survival (OS) between patient subcohorts divided by primary disease and stratified by targeted therapy receipt or IMD status. RESULTS: Post-IMD targeted therapy was associated with prolonged OS in patients with HER2-positive breast cancer (HR 0.41; 95% CI, 0.33–0.5), EGFR-positive lung cancer (HR 0.28; 95% CI, 0.23–0.34), and BRAF-positive melanoma (HR 0.2; 95% CI, 0.14–0.29), compared to those who did not receive post-IMD targeted therapy. Presence of IMD was associated with shorter OS in patients with metastatic breast cancer (HR 1.8; 95% CI, 1.56–2.08) and metastatic EGFR-positive lung cancer (HR 1.22; 95% CI, 1.08–1.39) but not metastatic BRAF-positive melanoma (HR 1.11; 95% CI, 0.77–1.61), compared to those without IMD. CONCLUSIONS: Our findings show that real-world use of targeted therapies was associated with prolonged OS in patients with IMD in the setting of HER2-positive breast cancer, EGFR-positive lung cancer, and BRAF-positive melanoma. Inclusion of patients with IMD in clinical trials and use of endpoints that interrogate IMD will be critical to determine the role of targeted therapies in the management of patients with IMD.

MEDICAL THERAPY (CHEMOTHERAPY AND IMMUNOTHERAPY)

THER-01. TARGETED THERAPY AND INTRACRANIAL METASTATIC DISEASE: A POPULATION-BASED RETROSPECTIVE COHORT STUDY

Anders Erickson1, Steven Haldane2, Frances Wright3, Ansha Lofters4, Katarzyna Jerzak5, Sunit Dass5; 1Katholieke Universiteit Leuven, Faculty of Medicine, University of Toronto, Toronto, ON, Canada, 2Ontario Health Cancer Ontario), Toronto, ON, Canada, 3Division of General Surgery, Department of Surgery, Sunnybrook Hospital, University of Toronto, Toronto, ON, Canada, 4Department of Family Medicine, University of Toronto, Women’s College Hospital, Toronto, ON, Canada, 5Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada

BACKGROUND: Ovarian carcinoma with brain metastases is an uncommon but increasing phenomenon. PARP inhibitors (PARPI) are increasingly used as an adjunctive treatment in patients with central nervous system metastases (CNS). Historically brain metastases has a historically poor prognosis. Five women with a mean age of 60.4 ± 7.6 years were included. All had stage IIIC/IV ovarian cancer and diagnosed with brain metastases at recurrence. Three underwent resection for oligometastatic disease followed by post-operative stereotactic radiosurgery (SRS) and one with an operable tumour was treated with SRS without surgery. A fourth patient underwent whole brain radiotherapy for multiple metastases. Pathology was confirmed in those who were resected. Two patients had evidence of systemic disease in addition to CNS spread. Three women were BRCA1/2 Positive. Following initial surgery, one patient received adjuvant chemotherapy followed by olaparib maintenance, one received 13 cycles of bevacizumab/olaparib, followed by olaparib maintenance. A third patient was treated with olaparib/bevacizumab and two patients received olaparib monotherapy, both of whom continued on therapy. All received olaparib therapy during their treatment and all had minor dose modifications due to side effects. Mean survival from initial cancer diagnosis was 62.4 ± 20.4 months. Mean duration of PARP therapy was 27.6 ± 16.8 months. Mean survival following CNS recurrence was 22.8 ± 12 months. One patient is disease-free, two patients are alive with stable disease, one patient is alive but off treatment secondary to progression, and one patient is deceased secondary to progression of her brain metastases after being on PARP therapy for 18 months. The cohort remained highly functional across the trajectory of their disease with ECOG scores of 1 (n=4) or 0 (n=1). The results of this single institution retro-